ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5 February 2016, all resolutions were duly passed. Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma, said: “We are…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the…

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company“), the specialist drug discovery and development company, is pleased to announce the successful completion of the conditional fund raise, comprising the Placing and Subscription, announced earlier today. The Company has conditionally raised, in aggregate, £8.3 million (before expenses) by way of the placing of 14,901,800 new ordinary shares…

Proposed fundraising to finance the pivotal Phase III trial for the Company’s lead product, Lupuzor™ Friday, February 5, 2016 – 10:46 ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce a proposed conditional fund raise of not less than £7.5 million. This includes a proposed conditional…